Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers

Neurology

Volumn 81, Issue 15, 2013, Pages 1322-1331

  Jacova, Claudia ^a   Hsiung, Ging Yuek R ^a   Tawankanjanachot, Itthipol ^a   Dinelle, Katie ^a   McCormick, Siobhan ^a   Gonzalez, Marjorie ^a   Lee, Hyunsoo ^a   Sengdy, Pheth ^a   Bouchard Kerr, Phoenix ^a   Baker, Matthew ^b   Rademakers, Rosa ^b   Sossi, Vesna ^a   Stoessl, A Jon ^a   Feldman, Howard H ^a   Mackenzie, Ian R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; PROGRANULIN;

ADULT; AGED; ANGULAR GYRUS; ANTERIOR CINGULATE; ANTERIOR INSULA; ANTERIOR POSTERIOR AXIS; ARTICLE; BRAIN ASYMMETRY; BRAIN METABOLISM; CLINICAL ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; DRUG UPTAKE; FAMILIAL DISEASE; FEMALE; FRONTAL CORTEX; FRONTAL GYRUS; FRONTOTEMPORAL DEMENTIA; FUNCTIONAL RATING SCALE; GENE MUTATION; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HETEROZYGOTE; HUMAN; LEFT HEMISPHERE; MALE; MIDDLE TEMPORAL GYRUS; MINI MENTAL STATE EXAMINATION; MUTATIONAL ANALYSIS; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PARIETAL GYRUS; PONS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; RIGHT HEMISPHERE; SUPERIOR TEMPORAL GYRUS;

ADULT; AGED; BRAIN MAPPING; DEMENTIA; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; FRONTAL LOBE; GLUCOSE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUTATION; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES;

EID: 84888222366     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182a8237e     Document Type: Article

References (40)

1. Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006;442:916-919.
2. Cruts M, Gijselinck I, van der Zee J, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 2006;442:920-924.
3. Mackenzie IR. The neuropathology and clinical phenotype of FTD with progranulin mutations. Acta Neuropathol 2007;114:49-54.
4. Mackenzie IR, Neumann M, Baborie A, et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 2011;122:111-113.
5. Kelley BJ, Haidar W, Boeve BF, et al. Prominent phenotypic variability associated with mutations in Progranulin. Neurobiol Aging 2009;30:739-751.
6. Bruni AC, Momeni P, Bernardi L, et al. Heterogeneity within a large kindred with frontotemporal dementia: a novel progranulin mutation. Neurology 2007;69:140-147.
7. Whitwell JL, Jack CR Jr, Baker M, et al. Voxel-based morphometry in frontotemporal lobar degeneration with ubiquitin-positive inclusions with and without progranulin mutations. Arch Neurol 2007;64:371-376.
8. Whitwell JL, Weigand SD, Boeve BF, et al. Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain 2012;135:794-806.
9. Rohrer JD, Warren JD, Omar R, et al. Parietal lobe deficits in frontotemporal lobar degeneration caused by a mutation in the progranulin gene. Arch Neurol 2008;65:506-513.
10. Borroni B, Alberici A, Cercignani M, et al. Granulin mutation drives brain damage and reorganization from preclinical to symptomatic FTLD. Neurobiol Aging 2012;33:2506-2520.
11. Cruchaga C, Fernandez-Seara MA, Seijo-Martinez M, et al. Cortical atrophy and language network reorganization associated with a novel progranulin mutation. Cereb Cortex 2009;19:1751-1760.
12. Rohrer JD, Warren JD, Barnes J, et al. Mapping the progression of progranulin-associated frontotemporal lobar degeneration. Nat Clin Pract Neurol 2008;4:455-460.
13. Andreason PJ, Zametkin AJ, Guo AC, Baldwin P, Cohen RM. Gender-related differences in regional cerebral glucose metabolism in normal volunteers. Psychiatry Res 1994;51:175-183.
14. Gur RC, Mozley LH, Mozley PD, et al. Sex differences in regional cerebral glucose metabolism during a resting state. Science 1995;267:528-531.
15. Kipps CM, Hodges JR, Fryer TD, Nestor PJ. Combined magnetic resonance imaging and positron emission tomography brain imaging in behavioural variant frontotemporal degeneration: refining the clinical phenotype. Brain 2009;132:2566-2578.
16. Collins DL, Neelin P, Peters TM, Evans AC. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J Comput Assist Tomogr 1994;18:192-205.
17. Seeley WW, Crawford R, Rascovsky K, et al. Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia. Arch Neurol 2008;65:249-255.
18. Lowe VJ, Kemp BJ, Jack CR Jr, et al. Comparison of 18F-FDG and PiB PET in cognitive impairment. J NuclMed 2009;50:878-886.
19. Rohrer JD, Ridgway GR, Modat M, et al. Distinct profiles of brain atrophy in frontotemporal lobar degeneration caused by progranulin and tau mutations. Neuroimage 2010;53:1070-1076.
20. Frackowiak RS, Friston KJ, Frith CD, et al. Human Brain Function, 2nd ed. Philadelphia: Elsevier; 2004.
21. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1999;51:1546-1554.
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: IV-TR. Washington, DC: American Psychiatric Association; 2000.
23. Brinkmann BH, Jones DT, Stead M, et al. Statistical parametric mapping demonstrates asymmetric uptake with Tc-99m ECD and Tc-99m HMPAO SPECT in normal brain. J Cereb Blood Flow Metab 2012;32:190-198.
24. Drzezga A, Lautenschlager N, Siebner H, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 2003;30:1104-1113.
25. Nestor PJ, Caine D, Fryer TD, Clarke J, Hodges JR. The topography of metabolic deficits in posterior cortical atrophy (the visual variant of Alzheimer's disease) with FDG-PET. J Neurol Neurosurg Psychiatry 2003;74:1521-1529.
26. Whitwell JL, Josephs KA. Neuroimaging in frontotemporal lobar degeneration: predicting molecular pathology. Nat Rev Neurol 2011;8:131-142.
27. Spina S, Murrell JR, Huey ED, et al. Clinicopathologic features of frontotemporal dementia with progranulin sequence variation. Neurology 2007;68:820-827.
28. Raczka KA, Becker G, Seese A, et al. Executive and behavioral deficits share common neural substrates in frontotemporal lobar degeneration: a pilot FDG-PET study. Psychiatry Res 2010;182:274-280.
29. Viskontas IV, Possin KL, Miller BL. Symptoms of frontotemporal dementia provide insights into orbitofrontal cortex function and social behavior. Ann NY Acad Sci 2007;1121:528-545.
30. McDade E, Boeve BF, Burrus TM, et al. Similar clinical and neuroimaging features in monozygotic twin pair with mutation in progranulin. Neurology 2012;78:1245-1249.
31. Gass J, Prudencio M, Stetler C, Petrucelli L. Progranulin: an emerging target for FTLD therapies. Brain Res 2012;1462:118-128.
32. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) Examination. J Clin Psychiatry 1987;48:314-318.
33. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology 2000;55:1621-1626.
34. Kertesz A, Davidson W, Fox H. Frontal behavioral inventory: diagnostic criteria for frontal lobe dementia. Can J Neurol Sci 1997;24:29-36.
35. Crockett D, Tuokko H, Koch W, Parks R. The assessment of everyday functioning using the present functioning questionnaire and the functional rating scale in elderly samples. Clin Gerontologist 1989;8:3-25.
36. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory. Neurology 1994;44:2308-2314.
37. Goetz CG, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord 2007;22:41-47.
38. Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function: BDNF ALS Study Group (Phase III). J Neurol Sci 1999;169:13-21.
39. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
40. Gelinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther 1999;53:471-481.